News

Learn more about the in-depth topics covered in the July 2024 print issue of Dermatology Times.

Data from a retrospective analysis demonstrated that patients with moderate to severe alopecia areata are at a higher risk of developing atopic dermatitis compared to those with mild alopecia areata.

PIH, more prominent in darker skin types, often leads to significant psychosocial distress and reduced quality of life.

Dermatology Times is looking back on the top stories in dermatology from the month of July.

In combination with cemiplimab, BNT111 contributed to statistically significant and improved overall response rates.

Dermatology Times is recapping our top expert interviews from the month of July.

Learn more about the in-depth topics covered in the July 2024 supplement of Dermatology Times.

A recent review called for gender-specific studies to enhance dermatological treatments and potentially revise guidelines.

Generation Z patients had lower atopic dermatitis severity but similar disease perception compared to Millennial patients.

Patients with acne also had higher rates of abnormal zinc and vitamin D levels, especially in severe cases.

Take a deep dive into the 3 approvals for various dermatological conditions this month.

From ER visits for dystrophic epidermolysis bullosa to rates of axillary hyperhidrosis, catch up on top pediatric insights from July.

Researchers noted how historical bias in dermatology research has impacted the understanding and treatment of conditions in darker skin.

Researchers reported gender differences among individuals with skin conditions and compared sociodemographic, clinical and psychological variables.

Researchers conducted an assessment of the Nationwide Emergency Department Sample to analyze frequency of visits attributed to young patients with DEB.

Approved down to the age of 6, the treatment is covered by 2 pharmacy benefit manager contracts to provide timely coverage.

Explore how BCs are supported through complex drug approvals and ensuring patients have access to prescribed medications.

Keep up with the latest headlines in dermatology from the past week, including new research from Northwestern University in Merkel cell carcinoma, the FDA's approval of deuruxolitinib for alopecia areata, and more.

In case you missed it, this week we had news about the FDA approval of deuruxolitinib for severe alopecia in adults, new nonmelanoma guidelines from the Dermatology Association of Radiation Therapy, Arcutis' submitted sNDA for roflumilast foam for scalp and body psoriasis, and more.

Investigators looked into pollutant-induced disruption of the skin barrier, increased transepidermal water loss, and heightened inflammatory responses.

Iltefat Hamzavi, MD, discusses the REGINA 007 phase 2 trial evaluating MK-6194 for the treatment of non-segmental vitiligo.

A recent study found psoriasis content deemed “unreliable” still obtained 850,000 likes.

The lotion effectively rebalanced the microbiota, reduced erythema and desquamation, and improved acne severity.

Along with the approval, Sun Pharma is introducing an access program to assist eligible patients in starting and adhering to the treatment.

Combining electrocoagulation with pharmacotherapy significantly reduced keloid scar volume by inhibiting collagen deposition, angiogenesis, and cell proliferation.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on how the publication has impacted their practice.

The study highlights the need for personalized treatments, suggesting that this combination therapy is most beneficial when tailored to individual risk profiles.

A systematic review of 31 studies found that patients with EBA responded well to rituximab with few adverse effects.

Compared to a stapling device, Xkin reduced scarring, pain, and infection risk more effectively in surgical and trauma wounds.

Data from numerous studies identified fluorouracil 5% as ranking the most effective across 3 outcomes.